AbbVie on Twitter
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
September 06, 2024
-
August 01, 2024
-
July 25, 2024
-
June 21, 2024
-
April 26, 2024
-
April 04, 2024
-
February 27, 2024
-
February 15, 2024
-
February 12, 2024
-
February 02, 2024
-
October 27, 2023
-
October 04, 2023
-
September 08, 2023
-
September 06, 2023
-
July 27, 2023
-
June 22, 2023
-
April 27, 2023
-
April 04, 2023
-
February 28, 2023
-
February 16, 2023
-
February 09, 2023
-
January 05, 2023
-
November 23, 2022
-
November 22, 2022
-
November 09, 2022
-
October 28, 2022
-
October 04, 2022
-
September 09, 2022
-
September 07, 2022
-
July 29, 2022
-
June 23, 2022
-
April 29, 2022
-
April 14, 2022
-
March 11, 2022-Companies will research, develop and commercialize novel dopamine receptor modulators for potential treatment of neuropsychiatric conditions
-
March 01, 2022- Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
-
February 17, 2022
-
February 02, 2022- Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent; Adjusted Diluted EPS of $12.70, an Increase of 20.3 Percent
-
December 16, 2021-- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite --
-
November 23, 2021
-
November 23, 2021
-
November 18, 2021- A new literature review published in Advances in Therapy reported that for patients with rheumatoid arthritis (RA), achieving remission was associated with medical cost savings compared with other disease activity levels
-
November 10, 2021
-
October 29, 2021- Reports Third-Quarter Diluted EPS of $1.78 on a GAAP Basis, an Increase of 38.0 Percent; Adjusted Diluted EPS of $3.33, an Increase of 17.7 Percent
-
October 11, 2021THE POWER OF YOU CAMPAIGN ADVOCATES FOR AWARENESS AND EMPOWERS CONFIDENCE
-
October 05, 2021
September 29, 2021-- Allergan Aesthetics and SkinBetter Science deliver Atlas for residents and program directors ---
September 27, 2021- 65% of respondents said they were not prepared to have their eyesight worsen as they got older
-
September 13, 2021- AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise
-
September 10, 2021
-
September 09, 2021
-
August 12, 2021
-
July 30, 2021- Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11
-
July 27, 2021- Extension builds on partnership established in 2014, extended in 2018
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Societal impact
 |
Our commitment to science is a commitment to better our society. Read our 2023 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2023 Annual Report on Form 10-K. Learn more
